ABCL AbCellera Biologics Inc. Insider Trading

Director Montalbano buys 20,000 ABCL shares at $4.77; holdings rise to 241,000 shares amid 160.6% annual revenue growth and -$43.2M net loss.

Director John S. Montalbano purchased 20,000 shares of AbCellera Biologics Inc. at $4.77 on 2026-05-14, increasing his holdings from 221,000 to 241,000 shares. The transaction occurs with the stock trading at $4.06 (37.7% below its 52-week high of $6.52), though the 90-day change shows +28.1% appreciation. AbCellera reported latest-quarter revenue of $8.3M with annual revenue growth of +160.6%, but remains unprofitable with net income of -$43.2M over the most recent full fiscal year, creating a fundamental tension between growth trajectory and profitability. Montalbano's prior three measurable purchases at this ticker yielded mixed 90-day outcomes ranging from -9.8% to +6.1%, with outcomes distributed between net positive and net negative performance.

Thermopylae Holdings (10% owner) purchases 38,000 shares of ABCL at $3.44; prior ABCL buys show 100% 90-day win rate.

Thermopylae Holdings, a 10% shareholder, acquired 38,000 shares at $3.44 on 2026-02-27, extending its stake to 56.13M shares. This transaction is part of a consistent buying pattern at ABCL: the insider's two prior measurable trades at this ticker (2025-03-11 and 2024-08-29) both delivered positive 90-day returns (+16.2% and +14.9%, respectively), a 100% timing success rate over the evaluated window. The current price of $3.82 sits -38.1% from the 52-week high but +5.5% over 30 days, indicating recovery momentum in a stock that remains distressed. AbCellera's fundamentals show severe unprofitability (net income of -$57.1M on revenue of $9.0M in the latest quarter), but management is executing aggressive growth (annual revenue growth of +160.6%), a tension that may explain the stock's volatility. The 10% holder's repeat accumulation at similar price levels—and the prior success of such purchases—suggests confidence in the recovery trajectory despite current losses.

CFO Andrew Booth purchases 42,600 shares of ABCL at $3.42, raising holdings to 195,600 shares amid -41.5% drawdown from 52-week high.

CFO Andrew Booth acquired 42,600 shares at $3.42 on 2026-02-27, increasing his position by 27.8% to 195,600 shares post-transaction. This purchase occurs as the stock trades at $3.61, down 41.5% from its 52-week high of $6.17, representing a sustained decline in valuation. The company is generating revenue growth of 160.6% year-over-year ($9.0M in the latest quarter) but remains deeply unprofitable with a full-year net income of -$57.1M, indicating significant ongoing losses despite rapid sales expansion. The timing coincides with substantial price depreciation, which may reflect elevated execution or profitability risk that the market is pricing in, warranting careful examination of whether the CFO's accumulation signals conviction in the company's path to profitability or represents exposure to continued operational headwinds.

Thermopylae Holdings (10% owner) bought 177,457 shares of ABCL at $3.27; stock now at $3.61, down 41.5% from 52-week high.

Thermopylae Holdings, already holding 56.10M shares (10% ownership), purchased an additional 177,457 shares at $3.27, adding 0.3% to its position. At the filing date the stock traded at $3.61, showing -7.4% over 30 days and -3.2% over 90 days, despite the company's revenue growing 160.6% year-over-year. The insider's same-ticker history at ABCL shows 2 of 2 prior buys achieved positive 90-day returns (+16.2% in March 2025 and +14.9% in August 2024), establishing a pattern of opportunistic buying ahead of recoveries. However, current valuation pressures—reflected in the -41.5% distance from the 52-week high and the company's unprofitable status ($-57.1M net income on $9.0M quarterly revenue)—suggest the insider is purchasing during a sustained period of underperformance despite strong topline growth. The continued accumulation by a 10% owner during a downturn warrants attention to whether this reflects confidence in the company's path to profitability or mechanical rebalancing given the position's significance.

Director Montalbano buys 50,000 shares of ABCL at $3.57 (29.2% increase to 221,000 holdings) amid -41.0% YTD decline and -$57.1M annual net loss.

Montalbano's purchase of 50,000 shares for $178,460.00 represents a substantial 29.2% increase to his ABCL stake, now totaling 221,000 shares. The timing follows steep near-term price deterioration: the stock has fallen -41.0% from its 52-week high of $6.17 and -36.9% over the past 30 days. However, this buy occurs in the context of fundamental headwinds—the company reported annual net income of $-57,119,000.00, annual revenue decline of -24.2%, and latest quarterly revenue of only $8,955,000.00. His prior two measurable buys at ABCL (conducted in March 2025) generated positive 90-day returns of +6.1% and +3.3%, establishing a pattern of well-timed entry points at this ticker, yet current stock weakness and material unprofitability warrant scrutiny into whether this purchase represents confidence or reflects the typical market dynamics of accumulation at depressed levels by insider decision-makers.

10% owner Thermopylae Holdings acquires 343,631 shares of ABCL at $2.16 amid 55% drawdown from 52-week high.

Thermopylae Holdings, a 10% shareholder in AbCellera, purchased 343,631 shares at $2.16 on 2025-03-11, increasing its stake to 56,143,640 shares. The transaction occurs against a backdrop of material weakness: ABCL is currently trading at $2.23, down 55.0% from its 52-week high of $4.96, and has declined 28.1% over the past 30 days and 23.4% over 90 days. AbCellera faces fundamental headwinds with annual revenue growth of -24.2% and net income of -$51,107,000.00, indicating sustained operating losses. Thermopylae's prior purchase at this ticker (2024-08-29) also resulted in a +14.9% 90-day return, consistent with its cross-ticker track record of 100% win-rate timing on buys, though the current stock action—sharp declines in recent periods—contrasts with the insider's historical success pattern at ABCL.

Director Montalbano buys 25,000 ABCL shares at $2.30; stock down -55.6% from 52-week high of $4.96

Director John S. Montalbano purchased 25,000 shares of AbCellera at $2.30 on 2025-03-10, increasing his holdings by 17.1% to 171,000 shares post-transaction. This purchase follows another buy by the same director four days prior on 2025-03-06, suggesting continued accumulation at depressed price levels; the stock is currently trading at $2.20, down -55.6% from its 52-week high of $4.96 and -29.0% over the past 30 days. AbCellera faces significant headwinds—the company reported Revenue of $6.5M in the latest quarter with a Net income loss of $-51.1M, annual revenue declining -24.2%, and the company was unprofitable over its most recent full fiscal year, suggesting the recent price weakness may reflect fundamental deterioration rather than a temporary dislocation. The director's near-simultaneous purchases at these low prices warrant observation as a potential contrarian signal, though his prior same-ticker trades remain too recent to evaluate timing pattern.

Director Montalbano bought 60,000 ABCL shares at $2.34 on 2025-03-06; stock down 42.9% from 52-week high, prior buys at this ticker showed 90d gains.

Montalbano purchased 60,000 shares at $2.34, increasing his holdings by 69.8% to 146,000 shares. The buy occurred while the stock trades at $2.33, down 42.9% from its 52-week high of $4.08 and down 31.1% over the prior 30 days. His prior two purchases at ABCL (2023-11-06 and 2023-11-08) both delivered positive 90-day returns (8.0% and 16.1%), establishing a pattern of well-timed accumulation at this ticker. However, the company reported negative net income of $-51.1M in the latest quarter, annual revenue declined 24.2% year-over-year, and profitability remains elusive. The confluence of significant insider accumulation at depressed prices alongside deteriorating fundamentals warrants investigation into whether this reflects contrarian conviction or misalignment between insider actions and financial reality.

Thermopylae Holdings (10% owner) purchased 283,516 shares of ABCL at $2.61; stock now at $2.53, down -57.6% from 52-week high.

Thermopylae Holdings, which owns 56,086,009 shares post-transaction (approximately 10% of the company), purchased an additional 283,516 shares at $2.61 on 2024-08-29 for $739,976.76 total value. The transaction occurred amid significant deterioration in the company's fundamentals and price trajectory: AbCellera reported revenue of $7,323,000.00 in its latest quarter with net income of $-36,930,000.00, and annual revenue growth contracted by -92.2% year-over-year. The stock has declined -21.7% over 30 days and -35.5% over 90 days, trading at $2.53 today, -57.6% below its 52-week high of $5.97. This purchase by a major shareholder occurs within a context of sustained operational and financial contraction, with the company unprofitable over its most recent full fiscal year.